Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, September 24, 2011

Daily pill 'could stop or even REVERSE multiple sclerosis'


  • Researchers in Canada discover low levels of brain chemicals in sufferers
  • Trials are already underway and could speed the drug's release for general use

Doctors have made an 'exciting' breakthrough that could lead to a new treatment to stop - or even reverse the symptoms - of multiple sclerosis. 

Researchers have discovered that people with MS have significantly lower levels of brain chemicals called neuro-steroids. 
Neuro-steroids help build brain cells and maintain their function, connecting different areas of activity in the brain. 

Scientists and neurologists at the University of Alberta in Edmonton, Canada believe that it would be possible to replace the missing chemical with a daily pill that would represent a completely different way of dealing with the disease that affects more than 85,000 people in the UK.

Dr Chris Power announced the discovery in a research paper in the latest issue of Brain. 

He said: 'This frankly is an exciting breakthrough and has huge potential. The role of neurosteroids in the brain has been known for some time but no one thought - until now - that they might play a role in MS.'


Read more: http://www.dailymail.co.uk/health/article-2040959/Daily-pill-stop-reverse-multiple-sclerosis.html#ixzz1YsDUK5IG


===========================================================
Remain CURRENT with Multiple Sclerosis news  and information 
REGISTER HERE   MS Views and News 
.
.Providing You with 'MS Views and News', is what we do 
.
On the 4th Wednesday of each month  
Listen-to StuMSRadio.com at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions 
.

"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service 
.. All contributions are tax deductible to the fullest extent allowed by law 
.===========================================================
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

Friday, September 23, 2011

Saskatchewan to enter partnership with U.S. on MS research of CCSVI


Information reported from Jason Kaye in Canada
Sept 23, 2011


REGINA -- The provincial government says it will pay for some Saskatchewan patients to participate in a multiple sclerosis clinical trial of the so-called "liberation" therapy in Albany, N.Y.


Health Minister Don McMorris said in a news release Friday that the province is finalizing a partnership with U.S researchers led by Dr. Gary Siskin, a vascular and interventional radiologist at Albany Medical Centre.


"Patients need answers as soon as possible about the efficacy of the liberation therapy as a treatment for MS," McMorris said in a statement. "We owe it to them to explore every opportunity to advance MS research and find answers about this treatment. This clinical study will enable Saskatchewan patients to be involved quite quickly in a controlled, reputable research process."


Saskatchewan MS patients will be advised how and when they can apply to participate after the partnership is finalized. The news release did not include an anticipated timeline. McMorris is scheduled to talk to reporters later this morning.

Read more: http://www.leaderpost.com/health/Sask+enter+partnership+with+research/5448443/story.html#ixzz1YocGNTQe






.

"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service 
.. All contributions are tax deductible to the fullest extent allowed by law 
.===========================================================
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

Thursday, September 22, 2011

New MS Research claims: Increasing steroids in the brains of multiple sclerosis patients may regress and possibly even cure the disease,


September 22, 2011 - EDMONTON - Increasing steroids in the brains of multiple sclerosis patients may regress and possibly even cure the disease, researchers at the University of Alberta said.

"We discovered that the genes that were responsible for making neurosteroids were suppressed (in MS patients)," said Dr. Chris Power, neurologist and researcher at the U of A.
MS attacks the brain and spinal cord, causing inflammation and damage that can lead to paralysis and sometimes blindness.
Neurosteroids allow brain cells to communicate, as well as enable repair and re-growth of cells.
Researchers studied the brains of people who had died from multiple sclerosis and found they showed lower levels of neurosteroids.


===========================================================
Remain CURRENT with Multiple Sclerosis news  and information 
REGISTER HERE   MS Views and News 
.
.Providing You with 'MS Views and News', is what we do 
.

"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service 
.. All contributions are tax deductible to the fullest extent allowed by law 
.===========================================================
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

Two out of Three Patients Report Discontinuing Tysabri Without Doctors' Advice


PatientsLikeMe Releases First in Series of Reports on Real-World Patient Experiences With Top Multiple Sclerosis Drugs
CAMBRIDGE, MA--(Marketwire - Sep 22, 2011) - In the first report of a series on Multiple Sclerosis (MS) disease modifying therapies (DMTs), PatientsLikeMe reveals that nearly two-thirds (64%) of patients who report discontinuing the use of Tysabri (n=323) did not cite "doctor's advice" as a reason. "Side effects too severe" and "did not seem to work" topped the other reasons cited by patients. The report goes on to reveal that patients stop Tysabri due to side effect severity less frequently than patients who discontinue other DMTs for that same reason. The PatientsLikeMe report is the first of five in a series focusing on how patients are experiencing and evaluating DMTs in the real world.
"People with MS and other conditions have become much more than just consumers of prescription medications, they are now customers who wield a high level of influence on treatment decisions," says David S. Williams III, Chief Marketing Officer at PatientsLikeMe. "The goal is maximizing health outcomes for patients. Clinicians can use the real-world insights from this report to collaborate better with patients in treatment planning while manufacturers can use them to better design adherence programs to reduce inappropriate discontinuation."
This 40-page report -- titled "Does Tysabri patient experience in the real world justify its value?" -- analyzes the experiences of more than 12,000 MS patients who are taking, or have taken, Tysabri or other DMTs. In the report, PatientsLikeMe evaluates:
  • Tysabri Price vs. Value: Is this drug appropriately priced given real-world evidence regarding efficacy and side effects?





 Continue reading





===========================================================
Remain CURRENT with Multiple Sclerosis news  and information 
REGISTER HERE   MS Views and News 
.
.Providing You with 'MS Views and News', is what we do 
.

"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service 
.. All contributions are tax deductible to the fullest extent allowed by law 
.===========================================================
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

Monday, September 19, 2011

Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial


Press Release Source: Adeona Pharmaceuticals, Inc. On Monday September 19, 2011, 8:57 am EDT
ANN ARBOR, Mich.Sept. 19, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc.  a developer of innovative medicines for serious central nervous system diseases, announced today that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta™ (oral estriol) drug candidate for relapsing-remitting multiple sclerosis (MS) in women, per the original protocol. The Company also announced that Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, UCLA Department of Neurology, and lead Principal Investigator of this Phase II clinical trial, has funding available to continue enrollment at all 15 centers, therefore, increasing the power of the trial. It is anticipated that the remaining grant funding will allow for the enrollment of an additional 10-20 patients.
"We are excited to announce the enrollment of the 150th MS patient in this clinical trial, achieving our original targeted goal for enrollment. I am also very pleased that we have funds available to continue enrolling additional patients in this landmark MS trial," said Dr. Voskuhl. "Of the 400,000 people in the U.S. afflicted with MS, approximately 85% are initially diagnosed with relapsing-remitting MS, which is characterized by relapses, or attacks of declining neurologic function, followed by periods of remission. As we continue to dose and monitor each MS patient enrolled in the trial over a two year period, we would expect to demonstrate a statistically significant reduction in the rate of relapses in the patients treated with oral Trimesta."

CONTINUE READING

===========================================================
Remain CURRENT with Multiple Sclerosis news  and information 
REGISTER HERE   MS Views and News 
.
.Providing You with 'MS Views and News', is what we do 
.
On the 4th Wednesday of each month  
Listen-to StuMSRadio.com at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions 
.

"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service 
.. All contributions are tax deductible to the fullest extent allowed by law 
.===========================================================
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.